Jyong Biotech targets urinary disorders with a novel botanical pipeline, but clinical and liquidity risks temper near-term ...

Gilead receives positive CHMP opinions under accelerated review from EMA for twice-yearly lenacapavir for HIV prevention: Foster City, California Saturday, July 26, 2025, 13:00 Hr ...

Investing.com -- Celcuity Inc. (NASDAQ: CELC) stock rose 5.2% after the clinical-stage biotechnology company announced it will hold a conference call on Monday, July 28, 2025, to reveal topline ...

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

New clinical trials are advancing treatments for cutaneous T-cell lymphoma, advanced solid tumors, pediatric sarcomas and ALK ...

Unpredictable FDA and funding woes delay crucial drug approvals, depriving thousands of patients access to vital treatments ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Context Therapeutics Inc. (NASDAQ: CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context ...

Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug ...

Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...